Aspira files Mayo Clinic lab services agreement

Aspira Women’s Health Inc. filed an amended report to provide the full Laboratory Services Agreement it entered into with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories.

Accepted by SEC EDGAR 03/25/2026 - 04:41 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K/A

Rhea-AI Filing Summary

Aspira Women’s Health Inc. filed an amended report to provide the full Laboratory Services Agreement it entered into with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories. The agreement is effective as of December 16, 2025 and had previously been disclosed as a material definitive agreement.

The amendment mainly adds the agreement as Exhibit 10.1 after completing redactions of private or confidential information. No financial results or other business updates are included beyond this contract filing.

8-K Event Classification

2 items: 1.01, 9.01

2 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aspira Women’s Health (AWHL) report in this amended 8-K?

Aspira Women’s Health filed an amended report to add the Laboratory Services Agreement with Mayo Clinic Laboratories as Exhibit 10.1. The agreement was previously disclosed but not filed until redactions of private or confidential information were completed.

Who is Aspira Women’s Health’s partner in the new Laboratory Services Agreement?

Aspira’s Laboratory Services Agreement is with Mayo Collaborative Services, Inc., doing business as Mayo Clinic Laboratories. The amendment formally files this agreement as an exhibit, reflecting its status as a material definitive agreement between the two organizations.

When did the Aspira–Mayo Clinic Laboratories agreement become effective?

The Laboratory Services Agreement between Aspira Women’s Health and Mayo Clinic Laboratories is effective as of December 16, 2025. The amended report filed later simply adds the finalized, partially redacted contract as Exhibit 10.1 for public reference.

Why did Aspira Women’s Health file an amendment to its Form 8-K?

Aspira filed the amendment because the Laboratory Services Agreement with Mayo Clinic Laboratories was not attached initially. The company needed additional time to finalize appropriate redactions of private or confidential information before including the contract as Exhibit 10.1.

Does this Aspira (AWHL) filing include new financial results or earnings data?

No, the filing focuses solely on attaching the Laboratory Services Agreement with Mayo Clinic Laboratories as a material definitive agreement. It does not provide revenue, earnings, or other financial performance data, and only updates the exhibit section of the prior report.

What exhibits are included in this Aspira Women’s Health amended report?

The amended report lists Exhibit 10.1, the Laboratory Services Agreement dated December 16, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document. These exhibits complete the earlier disclosure of the agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 23, 2025

ASPIRA WOMEN’S HEALTH INC.

(Exact name of registrant as specified in its charter)


Delaware		001-34810		33-0595156
(State or other jurisdiction of		(Commission		(IRS Employer
incorporation or organization)		File Number)		Identification No.)

12117 Bee Caves Road, Building III, Suite 100

Austin, TX 78738

(Address of principal executive office) (Zip Code)

(512) 519-0400

(Registrants’ telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	AWHL	OTC QX Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

Explanatory Note

On December 23, 2025, Aspira Women’s Health Inc. (“Aspira”) disclosed that we had entered into a Laboratory Services Agreement (the “Agreement”) with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories (“Mayo”), effective as of December 16, 2025.

The Agreement was not filed at the time of the 8-K filing as Aspira was still finalizing appropriate redactions of certain information that is private or confidential.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.


Exhibit No.		Description
10.1		Laboratory Services Agreement, dated as of December 16, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: March 25, 2026


	ASPIRA WOMEN’S HEALTH INC.

	By:	/s/ Brian Hungerford
	Name:	Brian Hungerford
	Title:	Chief Financial Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

EX-10.1 EX-10.1 82.4 KB